Q-omics provides the consensus-scored OAS2 profile across patient tissues and cancer cell-line models. OAS2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, OAS2 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, OAS2 protein abundance shows 16,762 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight SKCM, KIRC, and CCRCC as cancer lineages where OAS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OAS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OAS2 survival associations across molecular data types. OAS2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OAS2 RNA expression–survival associations across cancer types. High OAS2 expression shows unfavorable associations in KIRP, HNSC, LGG and PAAD, but favorable associations in SKCM and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for OAS2 RNA expression.
This table summarizes OAS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for OAS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OAS2 shows lower tumor expression in KICH and higher tumor expression in KIRC, HNSC, STAD, BRCA and BLCA. The KIRC box plot shows higher OAS2 RNA expression in tumor versus normal tissue (log2 FC = +1.608, t-test p < 0.001).
This table shows molecular features associated with OAS2 in patient tissues and cancer cell lines. In patient samples, OAS2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, OAS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
